This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 110/24/3721    most recent 01.CIR.0000146790.51331.BAv2 01.CIR.0000146790.51331.BAv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, Y.-X. Articles by O’Brien, E. R. Search for Related Content PubMed PubMed Citation Articles by Chen, Y.-X. Articles by O’Brien, E. R. Related Collections Primary prevention Restenosis Mechanism of atherosclerosis/growth factors Animal models of human disease

(Circulation. 2004;110:3721-3726.)
© 2004 American Heart Association, Inc.

Vascular Medicine

Novel Antiinflammatory Vascular Benefits of Systemic and Stent-Based Delivery of Ethylisopropylamiloride

From the University of Ottawa Heart Institute, Ottawa, Ontario, Canada.

Correspondence to Dr Edward O’Brien, Vascular Biology Laboratory, Division of Cardiology, Room H-263, University of Ottawa Heart Institute, Ottawa, Ontario, Canada K1Y4W7. E-mail eobrien{at}ottawaheart.ca

Received May 4, 2004; revision received July 23, 2004; accepted August 16, 2004.

Background— Recently, we demonstrated that the amiloride derivative ethylisopropylamiloride (EIPA) limits vascular smooth muscle cell growth and migration. The purpose of the present experiments was to determine whether EIPA can also reduce the inflammatory component of atherogenesis and stent neointima formation.

Methods and Results— To determine the effect of EIPA on the early inflammatory stages of atherogenesis, apolipoprotein E null mice (apoE^–/–) fed an atherogenic diet received a subcutaneous pump infusion of either EIPA (3 mg · kg^–1d^–1) or the control vehicle for 4 weeks. The en face aortic area of atherosclerotic lesions and the subendothelial accumulation of macrophages were reduced by 46% and 38%, respectively, in EIPA-treated mice. Moreover, the number of vascular cell adhesion molecule-1 (VCAM-1) immunopositive lumenal endothelial cells was 59% less in the EIPA treatment group. In vitro, there was a concentration-dependent inhibition of lipopolysaccharide (LPS)-induced VCAM-1 expression with a corresponding 37% reduction in U-937 cell adhesion to endothelial cells. EIPA also reduced LPS-stimulated nuclear factor-B (NF-B) activation as reflected by a 66% reduction in NF-B nuclear translocation. Finally, to test the effect of EIPA on the early inflammatory reaction to stent implantation, stents coated with jelly alone or jelly plus EIPA were implanted into rabbit iliac arteries. Four weeks later, the stent neointimal area, abundance of peristrut macrophages, and density of intimal smooth muscle cells were reduced by 38%, 47%, and 37%, respectively, for EIPA stents.

Conclusions— EIPA downregulates endothelial cell activation of NF-B and VCAM-1 expression and attenuates the early inflammatory stages of atherogenesis and stent intimal formation.

Key Words: atherosclerosis • cell adhesion molecules • inflammation • restenosis • stents

This article has been cited by other articles:

				A. Csiszar, K. Smith, N. Labinskyy, Z. Orosz, A. Rivera, and Z. Ungvari Resveratrol attenuates TNF-{alpha}-induced activation of coronary arterial endothelial cells: role of NF-{kappa}B inhibition. Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1694 - H1699. [Abstract] [Full Text] [PDF]

				P. Rippstein, M. K. Black, M. Boivin, J. P. Veinot, X. Ma, Y.-X. Chen, P. Human, P. Zilla, and E. R. O'Brien Comparison of Processing and Sectioning Methodologies for Arteries Containing Metallic Stents J. Histochem. Cytochem., June 1, 2006; 54(6): 673 - 681. [Abstract] [Full Text] [PDF]